PMID- 33511282
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2392-1099 (Print)
IS  - 2449-8238 (Electronic)
IS  - 2392-1099 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Dec
TI  - SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic 
      fatty liver disease complicated with type 2 diabetes mellitus: a systematic 
      review.
PG  - 339-346
LID - 10.5114/ceh.2020.102173 [doi]
AB  - AIM OF THE STUDY: To evaluate the efficacy of sodium/glucose cotransporter-2 
      inhibitors (SGLT2i) in improving hepatic fibrosis and steatosis of non-alcoholic 
      fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). 
      MATERIAL AND METHODS: We searched CENTRAL, MEDLINE, and EMBASE and included any 
      clinical trials involving patients with NAFLD and T2DM aged >/= 18 years comparing 
      efficacy of SGLT2i and other antidiabetic drugs in improving fibrosis and 
      steatosis, irrespective of publication status, year of publication, and language. 
      RESULTS: Five clinical trials were included. One study reported significant 
      improvements in the controlled attenuation parameter 314.6 +/-61.0 dB/m to 290.3 
      +/-72.7 dB/m (p = 0.04) in the SGLT2i group measured by transient elastography. In 
      patients with significant fibrosis, dapagliflozin treatment significantly 
      decreased the liver stiffness measurement from 14.7 +/-5.7 kPa at baseline to 11.0 
      +/-7.3 kPa after 24 weeks (p = 0.02). One study reported a significant decrease in 
      liver fat content 16.2% to 11.3% (p < 0.001) in the SGLT2i group compared to the 
      control (p < 0.001). Three studies reported significant improvement in the 
      liver-to-spleen ratio in the SGLT2i group after treatment 0.96 (0.86-1.07) to 
      1.07 (0.98-1.14), p < 0.01, 0.80 +/-0.24 to 1.00 +/-0.18, p < 0.001, and 0.91 
      (0.64-1.04) to 1.03 (0.80-1.20), p < 0.001 respectively. All studies reported a 
      significant decrease in alanine aminotransferase with SGLT2i. CONCLUSIONS: SGLT2i 
      is associated with positive effects on hepatic steatosis measured by non-invasive 
      modalities. Further studies are needed to confirm the impact of SGLT2i on hepatic 
      fibrosis and steatosis.
CI  - Copyright: (c) 2020 Clinical and Experimental Hepatology.
FAU - Dwinata, Michael
AU  - Dwinata M
AD  - Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, 
      Yogyakarta, Indonesia.
FAU - Putera, David Dwi
AU  - Putera DD
AD  - Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, 
      Yogyakarta, Indonesia.
FAU - Hasan, Irsan
AU  - Hasan I
AD  - Hepatobiliary Division, Department of Internal Medicine, Universitas Indonesia, 
      Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
FAU - Raharjo, Monica
AU  - Raharjo M
AD  - Hepatobiliary Division, Department of Internal Medicine, Universitas Indonesia, 
      Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20201230
PL  - Poland
TA  - Clin Exp Hepatol
JT  - Clinical and experimental hepatology
JID - 101703431
PMC - PMC7816633
OTO - NOTNLM
OT  - NAFLD
OT  - SGLT2 inhibitor
OT  - diabetes mellitus
OT  - fibrosis
OT  - steatosis
COIS- The authors declare no conflict of interest.
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
PMCR- 2020/12/01
CRDT- 2021/01/29 05:57
PHST- 2020/07/03 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2021/01/29 05:57 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - 42857 [pii]
AID - 10.5114/ceh.2020.102173 [doi]
PST - ppublish
SO  - Clin Exp Hepatol. 2020 Dec;6(4):339-346. doi: 10.5114/ceh.2020.102173. Epub 2020 
      Dec 30.